Federal Court of Appeal confirms obviousness finding in section 8 bortezomib action against Teva

Published date04 December 2019
Subject MatterPatents,Appeals,Obviousness,Dismissals,Reversible Error,Section 8,Patent Litigation,Pharmaceutical Patents,Canada,Patent Infringement,Teva Pharmaceuticals,Reaffirmation,Janssen Pharmaceuticals,Patent Invalidity,PMNOC Regulations
AuthorBrandon Heard
Law FirmSmart & Biggar

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT